Shenzhen Haibin Pharmaceutical Co., Ltd.

1) To evaluate the drug concentration of tobramycin inhalation solution in pulmonary epithelial lining fluid (ELF) and serum and the permeability of ELF to blood after multiple administration in patients with bronchiectasis (bronchiectasis) and Pseudomonas aeruginosa (PA) infection; 2) To evaluate the long-term (12-week) dosing regimen of tobramycin inhalation solution to treat the changes in bacteriological indicators in patients with bronchiectasis and PA infection; 3) To study the pharmacokinetics (PK)/pharmacodynamics (PD) and efficacy correlation of tobramycin inhalation solution in patients with bronchiectasis and PA infection after multiple administration.

Part 1 Multiple Ascending Dose (MAD) Phase for Patients Postoperatively Undergoing Laparoscopic Surgery: Primary Objective: To evaluate the safety and tolerability of multiple-dose administration of JKN2306 tablets in patients undergoing laparoscopic surgery. Secondary Objective: To evaluate the pharmacokinetic (PK) characteristics of multiple-dose administration of JKN2306 tablets in patients undergoing laparoscopic surgery. Exploratory Objectives: 1) To investigate the preliminary efficacy of multiple-dose administration of JKN2306 tablets in patients undergoing laparoscopic surgery; 2) To investigate the effects of JKN2306 on the activities of transporters or metabolic enzymes. Part 2: Dose-finding Phase for Patients Following Laparoscopic or Thoracoscopic Surgery: Primary Objective: To evaluate the efficacy of JKN2306 tablets in patients undergoing laparoscopic or thoracoscopic surgery. Secondary Objective: To evaluate the safety of JKN2306 tablets in patients undergoing laparoscopic or thoracoscopic surgery. Exploratory Objectives: 1) To investigate the preliminary efficacy of JKN2306 tablets in patients undergoing thoracoscopic or thoracoscopic surgery; 2) To explore the establishment of a population pharmacokinetic (popPK) model for JKN2306 in patients undergoing laparoscopic or thoracoscopic surgery.

Preliminary exploration of the changes in sputum PA in patients with acute exacerbation of bronchiectasis and PA infection treated with tobramycin nebulized inhalation on the basis of systemic anti-infection.